Does the media prefer JAZZ or AXSM?

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 11 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.29 beat Axsome Therapeutics' score of 0.15 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RPRX or AXSM?

In the previous week, Axsome Therapeutics had 6 more articles in the media than Royalty Pharma. MarketBeat recorded 11 mentions for Axsome Therapeutics and 5 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.00 beat Axsome Therapeutics' score of 0.15 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ZTS or AXSM?

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.19 $2.67B $6.07 12.04 Axsome Therapeutics $776.57M 11.47 -$183.17M -$3.75 N/A

Is ZTS or AXSM more profitable?

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% Axsome Therapeutics -24.68% -265.55% -28.10%

Does the media favor ZTS or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Zoetis. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Zoetis. Zoetis' average media sentiment score of 0.43 beat Axsome Therapeutics' score of 0.15 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AXSM or VTRS more profitable?

Viatris has a net margin of -2.79% compared to Axsome Therapeutics' net margin of -24.68%. Viatris' return on equity of 20.02% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -24.68% -265.55% -28.10% Viatris -2.79% 20.02% 8.02%

Does the media refer more to AXSM or VTRS?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Viatris. Viatris' average media sentiment score of 0.39 beat Axsome Therapeutics' score of 0.15 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to AXSM or NBIX?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 7 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.60 beat Axsome Therapeutics' score of 0.15 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Axsome Therapeutics (AXSM) Competitors

$168.35 -1.73 (-1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$168.25 -0.10 (-0.06%)

As of 04:50 PM Eastern

Compare

AXSM vs. JAZZ, RPRX, ZTS, VTRS, and NBIX

Should you buy Axsome Therapeutics stock or one of its competitors? Axsome Therapeutics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), and Neurocrine Biosciences (NBIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 11 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.29 beat Axsome Therapeutics' score of 0.15 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Jazz Pharmaceuticals presently has a consensus target price of $291.25, indicating a potential upside of 30.93%. Axsome Therapeutics has a consensus target price of $275.74, indicating a potential upside of 62.12%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.38	-$356.15M	$14.50	15.34
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Royalty Pharma currently has a consensus target price of $61.57, suggesting a potential upside of 9.54%. Axsome Therapeutics has a consensus target price of $275.74, suggesting a potential upside of 62.12%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Royalty Pharma has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Axsome Therapeutics' net margin of -24.68%. Royalty Pharma's return on equity of 30.01% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Axsome Therapeutics had 6 more articles in the media than Royalty Pharma. MarketBeat recorded 11 mentions for Axsome Therapeutics and 5 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.00 beat Axsome Therapeutics' score of 0.15 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.59	$770.95M	$1.45	38.77
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A

Summary

Royalty Pharma beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.19	$2.67B	$6.07	12.04
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A

Zoetis has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

In the previous week, Axsome Therapeutics had 5 more articles in the media than Zoetis. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Zoetis. Zoetis' average media sentiment score of 0.43 beat Axsome Therapeutics' score of 0.15 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zoetis presently has a consensus price target of $101.08, suggesting a potential upside of 38.32%. Axsome Therapeutics has a consensus price target of $275.74, suggesting a potential upside of 62.12%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Zoetis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Zoetis beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Viatris?

Axsome Therapeutics (NASDAQ:AXSM) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Viatris has a net margin of -2.79% compared to Axsome Therapeutics' net margin of -24.68%. Viatris' return on equity of 20.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Viatris	-2.79%	20.02%	8.02%

Axsome Therapeutics currently has a consensus target price of $275.74, indicating a potential upside of 62.12%. Viatris has a consensus target price of $20.50, indicating a potential upside of 17.55%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Viatris	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Axsome Therapeutics had 2 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Viatris. Viatris' average media sentiment score of 0.39 beat Axsome Therapeutics' score of 0.15 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Viatris has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Axsome Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A
Viatris	$14.30B	1.40	-$3.51B	-$0.36	N/A

Summary

Axsome Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Neurocrine Biosciences?

Axsome Therapeutics (NASDAQ:AXSM) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Axsome Therapeutics currently has a consensus target price of $275.74, indicating a potential upside of 62.12%. Neurocrine Biosciences has a consensus target price of $202.05, indicating a potential upside of 43.04%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83

Neurocrine Biosciences has a net margin of 20.91% compared to Axsome Therapeutics' net margin of -24.68%. Neurocrine Biosciences' return on equity of 22.43% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Axsome Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 7 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.60 beat Axsome Therapeutics' score of 0.15 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A
Neurocrine Biosciences	$2.86B	5.02	$478.60M	$6.82	20.71

Summary

Neurocrine Biosciences beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.82B	$12.36B	$7.20B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	-44.89	795.16	274.48	26.17
Price / Sales	11.36	834.83	585.26	80.91
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	96.20	10.71	11.21	6.34
Net Income	-$183.17M	$2.84B	$3.50B	$381.90M
7 Day Performance	-6.08%	-0.99%	-0.85%	-1.38%
1 Month Performance	-20.07%	-5.86%	-5.44%	-4.30%
1 Year Performance	37.41%	-5.32%	4.34%	-0.35%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	3.2839 of 5 stars	$168.35 -1.0%	$275.74 +63.8%	+43.3%	$8.82B	$776.57M	N/A	925	Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.2728 of 5 stars	$236.04 +0.2%	$291.15 +23.3%	+61.5%	$15.30B	$4.27B	16.28	2,890	Analyst Forecast Insider Trade
RPRX Royalty Pharma	4.3824 of 5 stars	$56.66 -0.9%	$61.29 +8.2%	+56.1%	$32.87B	$2.54B	39.08	100	Analyst Forecast
ZTS Zoetis	4.8896 of 5 stars	$71.41 +2.5%	$101.08 +41.6%	-49.1%	$28.80B	$9.47B	11.76	14,500	Dividend Announcement
VTRS Viatris	2.886 of 5 stars	$17.62 +0.1%	$20.50 +16.3%	+74.9%	$20.22B	$14.30B	N/A	30,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, RPRX, ZTS, VTRS, and NBIX

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Summary

How does Axsome Therapeutics compare to Zoetis?

Summary

How does Axsome Therapeutics compare to Viatris?

Summary

How does Axsome Therapeutics compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, RPRX, ZTS, VTRS, and NBIX

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Does the media prefer JAZZ or AXSM?

Do insiders and institutionals believe in JAZZ or AXSM?

Which has more risk & volatility, JAZZ or AXSM?

Do analysts prefer JAZZ or AXSM?

Is JAZZ or AXSM more profitable?

Which has preferable valuation & earnings, JAZZ or AXSM?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Do analysts recommend RPRX or AXSM?

Which has more risk & volatility, RPRX or AXSM?

Is RPRX or AXSM more profitable?

Do insiders & institutionals hold more shares of RPRX or AXSM?

Does the media refer more to RPRX or AXSM?

Which has better valuation and earnings, RPRX or AXSM?

Summary

How does Axsome Therapeutics compare to Zoetis?

Which has better earnings and valuation, ZTS or AXSM?

Which has more risk & volatility, ZTS or AXSM?

Do insiders and institutionals have more ownership in ZTS or AXSM?

Is ZTS or AXSM more profitable?

Does the media favor ZTS or AXSM?

Do analysts prefer ZTS or AXSM?

Summary

How does Axsome Therapeutics compare to Viatris?

Is AXSM or VTRS more profitable?

Do analysts recommend AXSM or VTRS?

Does the media refer more to AXSM or VTRS?

Do insiders & institutionals believe in AXSM or VTRS?

Which has more risk & volatility, AXSM or VTRS?

Which has stronger earnings & valuation, AXSM or VTRS?

Summary

How does Axsome Therapeutics compare to Neurocrine Biosciences?

Do insiders and institutionals believe in AXSM or NBIX?

Do analysts rate AXSM or NBIX?

Is AXSM or NBIX more profitable?

Which has more volatility and risk, AXSM or NBIX?

Does the media refer more to AXSM or NBIX?

Which has stronger valuation and earnings, AXSM or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools